Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
CANCER:
Mediastinal B Cell Lymphoma
Associations
(10)
News
Trials
A1 | Sensitive
A2 | Sensitive
B | Sensitive
C3 | Sensitive
A1 | Resistant
A2 | Resistant
B | Resistant
C3 | Resistant
Show legend
Group by Gene:
Drug categories
Immunotherapy
CD Protein Inhibitors
Immune Checkpoint Inhibitors
Cancel
CD19-targeted CAR-T immunotherapy
axicabtagene ciloleucel
lisocabtagene maraleucel
CD20 inhibitor
rituximab
PD1 inhibitor
pembrolizumab
CD3 agonist, CD20 inhibitor
epcoritamab-bysp
CD20-targeted CAR-T immunotherapy, CD19-targeted CAR-T immunotherapy
IMPT-314
No biomarker
A1
No biomarker
|
Mediastinal B Cell Lymphoma
|
axicabtagene ciloleucel
A1
No biomarker
|
Mediastinal B Cell Lymphoma
|
lisocabtagene maraleucel
A2
No biomarker
|
Mediastinal B Cell Lymphoma
|
rituximab
A1
No biomarker
|
Mediastinal B Cell Lymphoma
|
pembrolizumab
A1
No biomarker
|
Mediastinal B Cell Lymphoma
|
epcoritamab-bysp
B
No biomarker
|
Mediastinal B Cell Lymphoma
|
IMPT-314
MYC rearrangement
C3
MYC rearrangement
|
Mediastinal B Cell Lymphoma
|
rituximab
BCL6 rearrangement
C3
BCL6 rearrangement
|
Mediastinal B Cell Lymphoma
|
rituximab
MYC overexpression
C3
MYC overexpression
|
Mediastinal B Cell Lymphoma
|
lisocabtagene maraleucel
EZH2 overexpression
C3
EZH2 overexpression
|
Mediastinal B Cell Lymphoma
|
lisocabtagene maraleucel
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
